start-ver=1.4 cd-journal=joma no-vol=77 cd-vols= no-issue=1 article-no= start-page=11 end-page=19 dt-received= dt-revised= dt-accepted= dt-pub-year=2023 dt-pub=202302 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Safety and Efficacy of a Well-Fitting Brassiere after Breast Reconstruction: A Qualitative Study en-subtitle= kn-subtitle= en-abstract= kn-abstract=The importance of a well-fitted, comfortable brassiere to overall quality of life after breast reconstruction has not been evaluated. Our aim was to determine the impact of a semi-customized brassiere on patients’ health-related quality of life after breast reconstruction. The subjects were prospective patients with mastectomy who were to undergo immediate or delayed breast reconstruction at our hospital. After surgery, a professional bra fitter sized each patient for a semi-customized brassiere and provided follow-up consultations. A self-reported questionnaire on breast aesthetics, postoperative pain, and satisfaction was used to assess the primary outcomes. Data were prospectively collected at baseline (before surgery) and at 1, 3, 6, and 12 months after surgery and analyzed. Forty-six patients (50 breasts) were included in the analysis. Consistent wearing of the brassiere reduced pain (p<0.05), with good overall satisfaction (p<0.001). Aesthetic scores on breast shape and size were higher with than without the custom brassiere at 3 months (p=0.02) and 6 months (p=0.03) after surgery. Wearing the brassiere reduced anxiety at all time points of measurement. A well-fitting brassiere ensured safety and provided a high degree of satisfaction without anxiety for patients after breast reconstruction. en-copyright= kn-copyright= en-aut-name=WatanabeSatoko en-aut-sei=Watanabe en-aut-mei=Satoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=SaigaMiho en-aut-sei=Saiga en-aut-mei=Miho kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KimataYoshihiro en-aut-sei=Kimata en-aut-mei=Yoshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital kn-affil= affil-num=3 en-affil=Department of General Surgery, Okayama Saiseikai General Hospital kn-affil= affil-num=4 en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital kn-affil= affil-num=6 en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital kn-affil= affil-num=7 en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital kn-affil= en-keyword=breast reconstruction kn-keyword=breast reconstruction en-keyword=mastectomy kn-keyword=mastectomy en-keyword=brassiere kn-keyword=brassiere en-keyword=professional bra fitter kn-keyword=professional bra fitter END start-ver=1.4 cd-journal=joma no-vol=70 cd-vols= no-issue=5 article-no= start-page=425 end-page=427 dt-received= dt-revised= dt-accepted= dt-pub-year=2016 dt-pub=201610 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=A Phase I Trial of 100mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer en-subtitle= kn-subtitle= en-abstract= kn-abstract=Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. en-copyright= kn-copyright= en-aut-name=TamuraTomoki en-aut-sei=Tamura en-aut-mei=Tomoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=HirataTaizo en-aut-sei=Hirata en-aut-mei=Taizo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=HinotsuShiro en-aut-sei=Hinotsu en-aut-mei=Shiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=HamadaAkinobu en-aut-sei=Hamada en-aut-mei=Akinobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MizooTaeko en-aut-sei=Mizoo en-aut-mei=Taeko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= affil-num=1 en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of Medical Oncology, National Hospital Organization Kure Medical Center kn-affil= affil-num=3 en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital kn-affil= affil-num=4 en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital kn-affil= affil-num=5 en-affil=Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center kn-affil= affil-num=6 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=7 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=8 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=9 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=10 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=11 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=12 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= affil-num=13 en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital kn-affil= en-keyword=breast cancer kn-keyword=breast cancer en-keyword=phase I trial kn-keyword=phase I trial en-keyword=docetaxel kn-keyword=docetaxel END start-ver=1.4 cd-journal=joma no-vol=69 cd-vols= no-issue=6 article-no= start-page=333 end-page=338 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=201512 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast en-subtitle= kn-subtitle= en-abstract= kn-abstract=We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients. en-copyright= kn-copyright= en-aut-name=ItoMaiko en-aut-sei=Ito en-aut-mei=Maiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KajiMitsumasa en-aut-sei=Kaji en-aut-mei=Mitsumasa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MizooTaeko en-aut-sei=Mizoo en-aut-mei=Taeko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=MiyoshiShinichiro en-aut-sei=Miyoshi en-aut-mei=Shinichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=2 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=3 en-affil= kn-affil=Okayama Diagnostic Imaging Center affil-num=4 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=5 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=6 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=7 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=8 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=9 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=10 en-affil= kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences en-keyword=breast cancer kn-keyword=breast cancer en-keyword=invasive ductal carcinoma kn-keyword=invasive ductal carcinoma en-keyword=18F-fluorodeoxyglucose positron emission tomography/computed tomography kn-keyword=18F-fluorodeoxyglucose positron emission tomography/computed tomography en-keyword=maximum standardized uptake values kn-keyword=maximum standardized uptake values en-keyword=clinicopathological features kn-keyword=clinicopathological features END start-ver=1.4 cd-journal=joma no-vol=69 cd-vols= no-issue=5 article-no= start-page=291 end-page=299 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=201510 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer:NACED-Randomized Multicenter Phase II Trial en-subtitle= kn-subtitle= en-abstract= kn-abstract=Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies. en-copyright= kn-copyright= en-aut-name=SugiuKumi en-aut-sei=Sugiu en-aut-mei=Kumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KellyCatherine M. en-aut-sei=Kelly en-aut-mei=Catherine M. kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=WatanabeNaoki en-aut-sei=Watanabe en-aut-mei=Naoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ItohMitsuya en-aut-sei=Itoh en-aut-mei=Mitsuya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=OhtaniShoichiro en-aut-sei=Ohtani en-aut-mei=Shoichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=HigakiKenji en-aut-sei=Higaki en-aut-mei=Kenji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=ImadaTakako en-aut-sei=Imada en-aut-mei=Takako kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=YuasaTakeshi en-aut-sei=Yuasa en-aut-mei=Takeshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=OmoriMasako en-aut-sei=Omori en-aut-mei=Masako kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=SonobeHiroshi en-aut-sei=Sonobe en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=FujiwaraToshiyoshi en-aut-sei=Fujiwara en-aut-mei=Toshiyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= affil-num=1 en-affil= kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science affil-num=2 en-affil= kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science affil-num=3 en-affil= kn-affil=Department of Oncology, Mater Misericordiae University Hospital affil-num=4 en-affil= kn-affil=Department of Surgery, Chugoku Central Hospital affil-num=5 en-affil= kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science affil-num=6 en-affil= kn-affil=Department of Breast Surgery, Hiroshima City Hospital affil-num=7 en-affil= kn-affil=Department of Breast Surgery, Hiroshima City Hospita affil-num=8 en-affil= kn-affil=Department of Breast Surgery, Hiroshima City Hospital affil-num=9 en-affil= kn-affil=Department of Surgery, Okayama Central Hospital affil-num=10 en-affil= kn-affil=Department of Surgery, Himeji Red Cross Hospital affil-num=11 en-affil= kn-affil=Department of Pathology, Okayama University Hospital affil-num=12 en-affil= kn-affil=Department of Pathology, Chugoku Central Hospital affil-num=13 en-affil= kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science affil-num=14 en-affil= kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science b Department of Breast and Endocrine Surgery, Okayama University Hospital en-keyword=breast cancer kn-keyword=breast cancer en-keyword=neoadjuvant chemotherapy kn-keyword=neoadjuvant chemotherapy en-keyword=concurrent hormone therapy kn-keyword=concurrent hormone therapy en-keyword=estrogen receptor positive kn-keyword=estrogen receptor positive en-keyword=tumor response kn-keyword=tumor response END start-ver=1.4 cd-journal=joma no-vol=13 cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=20131201 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women en-subtitle= kn-subtitle= en-abstract= kn-abstract=Background: Lifestyle factors, including food and nutrition, physical activity, body composition and reproductive factors, and single nucleotide polymorphisms (SNPs) are associated with breast cancer risk, but few studies of these factors have been performed in the Japanese population. Thus, the goals of this study were to validate the association between reported SNPs and breast cancer risk in the Japanese population and to evaluate the effects of SNP genotypes and lifestyle factors on breast cancer risk. Methods: A case-control study in 472 patients and 464 controls was conducted from December 2010 to November 2011. Lifestyle was examined using a self-administered questionnaire. We analyzed 16 breast cancer-associated SNPs based on previous GWAS or candidate-gene association studies. Age or multivariate-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were estimated from logistic regression analyses. Results: High BMI and current or former smoking were significantly associated with an increased breast cancer risk, while intake of meat, mushrooms, yellow and green vegetables, coffee, and green tea, current leisure-time exercise, and education were significantly associated with a decreased risk. Three SNPs were significantly associated with a breast cancer risk in multivariate analysis: rs2046210 (per allele OR = 1.37 [95% CI: 1.11-1.70]), rs3757318 (OR = 1.33[1.05-1.69]), and rs3803662 (OR = 1.28 [1.07-1.55]). In 2046210 risk allele carriers, leisure-time exercise was associated with a significantly decreased risk for breast cancer, whereas current smoking and high BMI were associated with a significantly decreased risk in non-risk allele carriers. Conclusion: In Japanese women, rs2046210 and 3757318 located near the ESR1 gene are associated with a risk of breast cancer, as in other Asian women. However, our findings suggest that exercise can decrease this risk in allele carriers. en-copyright= kn-copyright= en-aut-name=MizooTaeko en-aut-sei=Mizoo en-aut-mei=Taeko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NishiyamaKeiko en-aut-sei=Nishiyama en-aut-mei=Keiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=IshiharaSetsuko en-aut-sei=Ishihara en-aut-mei=Setsuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=KawaiHiroshi en-aut-sei=Kawai en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=KawasakiKensuke en-aut-sei=Kawasaki en-aut-mei=Kensuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=IshibeYouichi en-aut-sei=Ishibe en-aut-mei=Youichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=OgasawaraYutaka en-aut-sei=Ogasawara en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=KomoikeYoshifumi en-aut-sei=Komoike en-aut-mei=Yoshifumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= en-aut-name=MiyoshiShinichiro en-aut-sei=Miyoshi en-aut-mei=Shinichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=16 ORCID= affil-num=1 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=2 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=3 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=4 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=5 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=6 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=7 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=8 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=9 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg affil-num=10 en-affil= kn-affil=Okayama Saiseikai Gen Hosp, Dept Radiol affil-num=11 en-affil= kn-affil=Okayama Rousai Hosp, Dept Breast Surg affil-num=12 en-affil= kn-affil=Kagawa Prefectural Canc Detect Ctr, Dept Breast Surg affil-num=13 en-affil= kn-affil=Mizushima Kyodo Hosp, Dept Breast Surg affil-num=14 en-affil= kn-affil=Dept Breast & Endocrinol Surg affil-num=15 en-affil= kn-affil=Kinki Univ Hosp, Fac Med affil-num=16 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg en-keyword=Japanese women kn-keyword=Japanese women en-keyword=Asian kn-keyword=Asian en-keyword=Breast cancer kn-keyword=Breast cancer en-keyword=Lifestyle kn-keyword=Lifestyle en-keyword=Leisure-time exercise kn-keyword=Leisure-time exercise en-keyword=Parity kn-keyword=Parity en-keyword=Single nucleotide polymorphisms kn-keyword=Single nucleotide polymorphisms en-keyword=rs2046210 kn-keyword=rs2046210 en-keyword=rs3757318 kn-keyword=rs3757318 en-keyword=ESR1 kn-keyword=ESR1 END start-ver=1.4 cd-journal=joma no-vol=143 cd-vols= no-issue=2 article-no= start-page=403 end-page=409 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=201401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers en-subtitle= kn-subtitle= en-abstract= kn-abstract=We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR > 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy. en-copyright= kn-copyright= en-aut-name=ItohMitsuya en-aut-sei=Itoh en-aut-mei=Mitsuya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=NiikuraNaoki en-aut-sei=Niikura en-aut-mei=Naoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=HayashiNaoki en-aut-sei=Hayashi en-aut-mei=Naoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=OhtaniShoichiro en-aut-sei=Ohtani en-aut-mei=Shoichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=HigakiKenji en-aut-sei=Higaki en-aut-mei=Kenji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=FujiwaraToshiyoshi en-aut-sei=Fujiwara en-aut-mei=Toshiyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=SymmansW. Fraser en-aut-sei=Symmans en-aut-mei=W. Fraser kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=PusztaiLajos en-aut-sei=Pusztai en-aut-mei=Lajos kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= affil-num=1 en-affil= kn-affil=Okayama Univ affil-num=2 en-affil= kn-affil=Okayama Univ affil-num=3 en-affil= kn-affil=Okayama Univ affil-num=4 en-affil= kn-affil=Okayama Univ affil-num=5 en-affil= kn-affil=Okayama Univ affil-num=6 en-affil= kn-affil=Okayama Univ affil-num=7 en-affil= kn-affil=Okayama Univ affil-num=8 en-affil= kn-affil=Tokai Univ affil-num=9 en-affil= kn-affil=St Lukes Int Hosp affil-num=10 en-affil= kn-affil=Hiroshima City Hosp affil-num=11 en-affil= kn-affil=Hiroshima City Hosp affil-num=12 en-affil= kn-affil=Okayama Univ affil-num=13 en-affil= kn-affil=Okayama Univ affil-num=14 en-affil= kn-affil=Univ Texas MD Anderson Canc Ctr affil-num=15 en-affil= kn-affil=Yale Univ en-keyword=Estrogen receptor kn-keyword=Estrogen receptor en-keyword=Progesteron receptor kn-keyword=Progesteron receptor en-keyword=cDNA microarray kn-keyword=cDNA microarray en-keyword=Breast cancer kn-keyword=Breast cancer en-keyword=Hormone therapy kn-keyword=Hormone therapy END start-ver=1.4 cd-journal=joma no-vol=126 cd-vols= no-issue=1 article-no= start-page=25 end-page=30 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=20140401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer kn-title=早期乳癌におけるOne-step Nucleic Acid Amplification(OSNA)法によるセンチネルリンパ節転移診断の検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=　Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay. 　Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection. 　Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected. 　Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery. en-copyright= kn-copyright= en-aut-name=MizooTaeko en-aut-sei=Mizoo en-aut-mei=Taeko kn-aut-name=溝尾妙子 kn-aut-sei=溝尾 kn-aut-mei=妙子 aut-affil-num=1 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name=枝園忠彦 kn-aut-sei=枝園 kn-aut-mei=忠彦 aut-affil-num=2 ORCID= en-aut-name=ItoMaiko en-aut-sei=Ito en-aut-mei=Maiko kn-aut-name=伊藤麻衣子 kn-aut-sei=伊藤 kn-aut-mei=麻衣子 aut-affil-num=3 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name=野上智弘 kn-aut-sei=野上 kn-aut-mei=智弘 aut-affil-num=4 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name=岩本高行 kn-aut-sei=岩本 kn-aut-mei=高行 aut-affil-num=5 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=6 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name=平成人 kn-aut-sei=平 kn-aut-mei=成人 aut-affil-num=7 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=8 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name=土井原博義 kn-aut-sei=土井原 kn-aut-mei=博義 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=2 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=3 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=4 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=5 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=6 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=7 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=8 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 affil-num=9 en-affil= kn-affil=岡山大学病院　乳腺・内分泌外科 en-keyword=OSNA法（OSNA method） kn-keyword=OSNA法（OSNA method） en-keyword=センチネルリンパ節（sentinel lymph node） kn-keyword=センチネルリンパ節（sentinel lymph node） en-keyword=micrometastases kn-keyword=micrometastases en-keyword=CK-19 kn-keyword=CK-19 END start-ver=1.4 cd-journal=joma no-vol=14 cd-vols= no-issue=3 article-no= start-page=230 end-page=236 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=201303 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice en-subtitle= kn-subtitle= en-abstract= kn-abstract=Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I alpha (HIF-1 alpha), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 +/- 722.0; temsirolimus, 599.2 +/- 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome. en-copyright= kn-copyright= en-aut-name=NishikawaToshio en-aut-sei=Nishikawa en-aut-mei=Toshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=TakaokaMunenori en-aut-sei=Takaoka en-aut-mei=Munenori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=OharaToshiaki en-aut-sei=Ohara en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TomonoYasuko en-aut-sei=Tomono en-aut-mei=Yasuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=HaoHuifang en-aut-sei=Hao en-aut-mei=Huifang kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=BaoXiaohong en-aut-sei=Bao en-aut-mei=Xiaohong kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=FukazawaTakuya en-aut-sei=Fukazawa en-aut-mei=Takuya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=WangZhigang en-aut-sei=Wang en-aut-mei=Zhigang kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=SakuramaKazufumi en-aut-sei=Sakurama en-aut-mei=Kazufumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=FujiwaraYasuhiro en-aut-sei=Fujiwara en-aut-mei=Yasuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=ShirakawaYasuhiro en-aut-sei=Shirakawa en-aut-mei=Yasuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=YamatsujiTomoki en-aut-sei=Yamatsuji en-aut-mei=Tomoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=TanakaNoriaki en-aut-sei=Tanaka en-aut-mei=Noriaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=FujiwaraToshiyoshi en-aut-sei=Fujiwara en-aut-mei=Toshiyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= en-aut-name=NaomotoYoshio en-aut-sei=Naomoto en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=16 ORCID= affil-num=1 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=2 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=3 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=4 en-affil= kn-affil=Shigei Med Res Inst affil-num=5 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=6 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=7 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=8 en-affil= kn-affil=Inner Mongolia Univ, Coll Life Sci, Dept Biol affil-num=9 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=10 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=11 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=12 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=13 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=14 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=15 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol affil-num=16 en-affil= kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol en-keyword=temsirolimus kn-keyword=temsirolimus en-keyword=esophageal cancer kn-keyword=esophageal cancer en-keyword=mTOR kn-keyword=mTOR en-keyword=prolonged survival kn-keyword=prolonged survival en-keyword=molecular-targeted therapy kn-keyword=molecular-targeted therapy END start-ver=1.4 cd-journal=joma no-vol=67 cd-vols= no-issue=3 article-no= start-page=145 end-page=151 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=201306 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Association between Mammographic Breast Density and Lifestyle in Japanese Women en-subtitle= kn-subtitle= en-abstract= kn-abstract=A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, －0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, －0.196;p value, 0.0143) and number of deliveries (parameter estimate, －0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s. en-copyright= kn-copyright= en-aut-name=IshiharaSetsuko en-aut-sei=Ishihara en-aut-mei=Setsuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=TairaNaruto en-aut-sei=Taira en-aut-mei=Naruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KawasakiKensuke en-aut-sei=Kawasaki en-aut-mei=Kensuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=IshibeYouichi en-aut-sei=Ishibe en-aut-mei=Youichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MizooTaeko en-aut-sei=Mizoo en-aut-mei=Taeko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=NishiyamaKeiko en-aut-sei=Nishiyama en-aut-mei=Keiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=NogamiTomohiro en-aut-sei=Nogami en-aut-mei=Tomohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=DoiharaHiroyoshi en-aut-sei=Doihara en-aut-mei=Hiroyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=KomoikeYoshifumi en-aut-sei=Komoike en-aut-mei=Yoshifumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=SatoShuhei en-aut-sei=Sato en-aut-mei=Shuhei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=KanazawaSusumu en-aut-sei=Kanazawa en-aut-mei=Susumu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= affil-num=1 en-affil= kn-affil=Department of Radiology, Okayama Saiseikai General Hospital affil-num=2 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=3 en-affil= kn-affil=Department of Surgery, Kagawa Prefectural Cancer Detection Center affil-num=4 en-affil= kn-affil=Department of Surgery, Mizushima Kyodo Hospital affil-num=5 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=6 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=7 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=8 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=9 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=10 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=11 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=12 en-affil= kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital affil-num=13 en-affil= kn-affil=Department of Surgery, Kinki University Hospital affil-num=14 en-affil= kn-affil=Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=15 en-affil= kn-affil=Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences en-keyword=breast cancer kn-keyword=breast cancer en-keyword=mammographic breast density kn-keyword=mammographic breast density en-keyword=life style kn-keyword=life style en-keyword=body mass index kn-keyword=body mass index END start-ver=1.4 cd-journal=joma no-vol=124 cd-vols= no-issue=3 article-no= start-page=243 end-page=247 dt-received= dt-revised= dt-accepted= dt-pub-year=2012 dt-pub=20121203 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=A case of intracystic carcinoma of the breast showing pathological complete response by neoadjuvant chemotherapy kn-title=術前化学療法により壁が菲薄化し組織学的寛解（pCR）となった巨大嚢胞内乳癌の１例 en-subtitle= kn-subtitle= en-abstract= kn-abstract=　A 31-year-old woman presented to our hospital because of a lump 5cm in diameter in her right breast. Ultrasonography revealed a multilocular cystic mass with partial thickening of the wall and the septum. Core needle biopsy (CNB) of the septum confirmed invasive ductal carcinoma. The patient was administered neoadjuvant chemotherapy consisting of 12 cycles of weekly paclitaxel followed by 4 cycles of FEC (5FU, Epilubicin and cyclophosphamide). While the thickness of the wall and septum became thinner, the tumor size did not change in diameter. She underwent right mastectomy and sentinel node biopsy. Post-surgical histopathological findings showed a pathological complete response (pCR).
　We report a rare case of invasive ductal carcinoma presenting a multilobular phenotype which showed pCR by neoadjuvant chemotherapy despite no size reduction of the tumor. en-copyright= kn-copyright= en-aut-name=ImadaTakako en-aut-sei=Imada en-aut-mei=Takako kn-aut-name=今田孝子 kn-aut-sei=今田 kn-aut-mei=孝子 aut-affil-num=1 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=2 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=3 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name=岩本高行 kn-aut-sei=岩本 kn-aut-mei=高行 aut-affil-num=4 ORCID= en-aut-name=OomoriMasako en-aut-sei=Oomori en-aut-mei=Masako kn-aut-name=大森昌子 kn-aut-sei=大森 kn-aut-mei=昌子 aut-affil-num=5 ORCID= en-aut-name=IhaSigemichi en-aut-sei=Iha en-aut-mei=Sigemichi kn-aut-name=伊波茂道 kn-aut-sei=伊波 kn-aut-mei=茂道 aut-affil-num=6 ORCID= en-aut-name=HongoToshie en-aut-sei=Hongo en-aut-mei=Toshie kn-aut-name=本後登志江 kn-aut-sei=本後 kn-aut-mei=登志江 aut-affil-num=7 ORCID= en-aut-name=HenmiNoriko en-aut-sei=Henmi en-aut-mei=Noriko kn-aut-name=逸見典子 kn-aut-sei=逸見 kn-aut-mei=典子 aut-affil-num=8 ORCID= en-aut-name=MakabeMikio en-aut-sei=Makabe en-aut-mei=Mikio kn-aut-name=真壁幹夫 kn-aut-sei=真壁 kn-aut-mei=幹夫 aut-affil-num=9 ORCID= en-aut-name=NogamiHiromi en-aut-sei=Nogami en-aut-mei=Hiromi kn-aut-name=野上浩實 kn-aut-sei=野上 kn-aut-mei=浩實 aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学 affil-num=2 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学 affil-num=3 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学 affil-num=4 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学 affil-num=5 en-affil= kn-affil=岡山大学病院　病理診断科 affil-num=6 en-affil= kn-affil=岡山大福クリニック affil-num=7 en-affil= kn-affil=岡山大福クリニック affil-num=8 en-affil= kn-affil=岡山大福クリニック affil-num=9 en-affil= kn-affil=岡山中央病院 affil-num=10 en-affil= kn-affil=野上病院 en-keyword=嚢胞内乳癌（intracystic breast cancer） kn-keyword=嚢胞内乳癌（intracystic breast cancer） en-keyword=術前化学療法（neoadjuvant chemotherapy） kn-keyword=術前化学療法（neoadjuvant chemotherapy） en-keyword=組織学的完全奏功（pahthological CR） kn-keyword=組織学的完全奏功（pahthological CR） END start-ver=1.4 cd-journal=joma no-vol=122 cd-vols= no-issue=1 article-no= start-page=17 end-page=25 dt-received= dt-revised= dt-accepted= dt-pub-year=2010 dt-pub=20100401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits an anticancer effect in esophageal adenocarcinoma in vitro and in vivo kn-title=Focal adhesion kinase (FAK) と Insulin-like growth factor-I receptor (IGF-IR) に対するデュアルチロシンキナーゼ阻害剤の食道腺癌における抗腫瘍効果 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=WatanabeNobuyuki en-aut-sei=Watanabe en-aut-mei=Nobuyuki kn-aut-name=渡辺信之 kn-aut-sei=渡辺 kn-aut-mei=信之 aut-affil-num=1 ORCID= en-aut-name=TakaokaMunenori en-aut-sei=Takaoka en-aut-mei=Munenori kn-aut-name=髙岡宗徳 kn-aut-sei=髙岡 kn-aut-mei=宗徳 aut-affil-num=2 ORCID= en-aut-name=SakuramaKazufumi en-aut-sei=Sakurama en-aut-mei=Kazufumi kn-aut-name=櫻間一史 kn-aut-sei=櫻間 kn-aut-mei=一史 aut-affil-num=3 ORCID= en-aut-name=TomonoYasuko en-aut-sei=Tomono en-aut-mei=Yasuko kn-aut-name=友野靖子 kn-aut-sei=友野 kn-aut-mei=靖子 aut-affil-num=4 ORCID= en-aut-name=HatakeyamaShinji en-aut-sei=Hatakeyama en-aut-mei=Shinji kn-aut-name=畠山慎二 kn-aut-sei=畠山 kn-aut-mei=慎二 aut-affil-num=5 ORCID= en-aut-name=OhmoriOsamu en-aut-sei=Ohmori en-aut-mei=Osamu kn-aut-name=大森修 kn-aut-sei=大森 kn-aut-mei=修 aut-affil-num=6 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=7 ORCID= en-aut-name=ShirakawaYasuhiro en-aut-sei=Shirakawa en-aut-mei=Yasuhiro kn-aut-name=白川靖博 kn-aut-sei=白川 kn-aut-mei=靖博 aut-affil-num=8 ORCID= en-aut-name=YamatsujiTomoki en-aut-sei=Yamatsuji en-aut-mei=Tomoki kn-aut-name=山辻知樹 kn-aut-sei=山辻 kn-aut-mei=知樹 aut-affil-num=9 ORCID= en-aut-name=HaisaMinoru en-aut-sei=Haisa en-aut-mei=Minoru kn-aut-name=羽井佐実 kn-aut-sei=羽井佐 kn-aut-mei=実 aut-affil-num=10 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=11 ORCID= en-aut-name=BeerDavid G. en-aut-sei=Beer en-aut-mei=David G. kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=NagatsukaHitoshi en-aut-sei=Nagatsuka en-aut-mei=Hitoshi kn-aut-name=長塚仁 kn-aut-sei=長塚 kn-aut-mei=仁 aut-affil-num=13 ORCID= en-aut-name=TanakaNoriaki en-aut-sei=Tanaka en-aut-mei=Noriaki kn-aut-name=田中紀章 kn-aut-sei=田中 kn-aut-mei=紀章 aut-affil-num=14 ORCID= en-aut-name=NaomotoYoshio en-aut-sei=Naomoto en-aut-mei=Yoshio kn-aut-name=猶本良夫 kn-aut-sei=猶本 kn-aut-mei=良夫 aut-affil-num=15 ORCID= affil-num=1 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=2 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=3 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=4 en-affil= kn-affil=重井医学研究所 affil-num=5 en-affil= kn-affil=ノバルティスファーマ　筑波研究所 affil-num=6 en-affil= kn-affil=ノバルティスファーマ　筑波研究所 affil-num=7 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=8 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=9 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=10 en-affil= kn-affil=岡山市立市民病院　外科 affil-num=11 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=12 en-affil= kn-affil=ミシガン大学　胸部外科 affil-num=13 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　口腔病理学 affil-num=14 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=15 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 en-keyword=focal adhesion kinase (FAK) kn-keyword=focal adhesion kinase (FAK) en-keyword=バレット食道癌 kn-keyword=バレット食道癌 en-keyword=FAK阻害剤 kn-keyword=FAK阻害剤 END start-ver=1.4 cd-journal=joma no-vol=118 cd-vols= no-issue=2 article-no= start-page=127 end-page=129 dt-received= dt-revised= dt-accepted= dt-pub-year=2006 dt-pub=20060901 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Localization of nonpalpable breast cancers using VATS marking system under ultrasonographic guidance kn-title=非触知乳癌におけるVATSマーカーを用いたエコーガイド下マーキングの有用性 en-subtitle= kn-subtitle= en-abstract= kn-abstract=A preoperative tumor guiding system for nonpalpable breast cancer using a VATS guiding needle (Hakko Co., Ltd., Tokyo Japan) was reported. It was easy to introduce the guiding needle into breast cancers smaller than 1cm under ultrasonographic observation. Neither bleeding nor infection was experienced. Wound management was easy and painless. This guiding system is very useful for locating and managing nonpalpable breast cancers even in outpatient settings. en-copyright= kn-copyright= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=1 ORCID= en-aut-name=TabuchiYoko en-aut-sei=Tabuchi en-aut-mei=Yoko kn-aut-name=田渕陽子 kn-aut-sei=田渕 kn-aut-mei=陽子 aut-affil-num=2 ORCID= en-aut-name=ItoMitsuya en-aut-sei=Ito en-aut-mei=Mitsuya kn-aut-name=伊藤充矢 kn-aut-sei=伊藤 kn-aut-mei=充矢 aut-affil-num=3 ORCID= en-aut-name=OnoRyoko en-aut-sei=Ono en-aut-mei=Ryoko kn-aut-name=小野亮子 kn-aut-sei=小野 kn-aut-mei=亮子 aut-affil-num=4 ORCID= en-aut-name=ImadaTakako en-aut-sei=Imada en-aut-mei=Takako kn-aut-name=今田孝子 kn-aut-sei=今田 kn-aut-mei=孝子 aut-affil-num=5 ORCID= en-aut-name=MatsukawaHiroyosi en-aut-sei=Matsukawa en-aut-mei=Hiroyosi kn-aut-name=松川啓義 kn-aut-sei=松川 kn-aut-mei=啓義 aut-affil-num=6 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=7 ORCID= en-aut-name=NaomotoYoshio en-aut-sei=Naomoto en-aut-mei=Yoshio kn-aut-name=猶本良夫 kn-aut-sei=猶本 kn-aut-mei=良夫 aut-affil-num=8 ORCID= en-aut-name=KanazawaSusumu en-aut-sei=Kanazawa en-aut-mei=Susumu kn-aut-name=金澤右 kn-aut-sei=金澤 kn-aut-mei=右 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=2 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=3 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=4 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=5 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=6 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=7 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=8 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科 affil-num=9 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 放射線科 en-keyword=非触知乳癌 (nonpalpable breast cancer) kn-keyword=非触知乳癌 (nonpalpable breast cancer) en-keyword=マーキング (marking) kn-keyword=マーキング (marking) en-keyword=エコーガイド (guiding echo) kn-keyword=エコーガイド (guiding echo) en-keyword=VATS マーカー (VATS marker) kn-keyword=VATS マーカー (VATS marker) END start-ver=1.4 cd-journal=joma no-vol=118 cd-vols= no-issue=2 article-no= start-page=123 end-page=125 dt-received= dt-revised= dt-accepted= dt-pub-year=2006 dt-pub=20060901 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Duct lavage cytology for the detection of breast cancer: report of a case kn-title=乳管洗浄細胞診が診断に有効であった乳癌の一例 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Although many modalities have been established to diagnose breast cancers, it is sometimes difficult to reveal nonpalpable cases. Duct lavage cytology was originally established to reveal groups at high risk for breast cancers by detecting metaplastic ductal cells. We report here a case where duct lavage was useful for revealing a small cancer that had been undetected by repeated bloody nipple discharge and cytological examinations. Duct lavage cytology may be of use in cases where nipple discharge of unknown origin persists. en-copyright= kn-copyright= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=1 ORCID= en-aut-name=TabuchiYoko en-aut-sei=Tabuchi en-aut-mei=Yoko kn-aut-name=田渕陽子 kn-aut-sei=田渕 kn-aut-mei=陽子 aut-affil-num=2 ORCID= en-aut-name=OnoRyoko en-aut-sei=Ono en-aut-mei=Ryoko kn-aut-name=小野亮子 kn-aut-sei=小野 kn-aut-mei=亮子 aut-affil-num=3 ORCID= en-aut-name=ImadaTakako en-aut-sei=Imada en-aut-mei=Takako kn-aut-name=今田孝子 kn-aut-sei=今田 kn-aut-mei=孝子 aut-affil-num=4 ORCID= en-aut-name=UmeokaTatsuo en-aut-sei=Umeoka en-aut-mei=Tatsuo kn-aut-name=梅岡達生 kn-aut-sei=梅岡 kn-aut-mei=達生 aut-affil-num=5 ORCID= en-aut-name=WatanabeNaoki en-aut-sei=Watanabe en-aut-mei=Naoki kn-aut-name=渡辺直樹 kn-aut-sei=渡辺 kn-aut-mei=直樹 aut-affil-num=6 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=7 ORCID= en-aut-name=MatsukawaHiroyosi en-aut-sei=Matsukawa en-aut-mei=Hiroyosi kn-aut-name=松川啓義 kn-aut-sei=松川 kn-aut-mei=啓義 aut-affil-num=8 ORCID= en-aut-name=NaomotoYoshio en-aut-sei=Naomoto en-aut-mei=Yoshio kn-aut-name=猶本良夫 kn-aut-sei=猶本 kn-aut-mei=良夫 aut-affil-num=9 ORCID= en-aut-name=TanakaNoriaki en-aut-sei=Tanaka en-aut-mei=Noriaki kn-aut-name=田中紀章 kn-aut-sei=田中 kn-aut-mei=紀章 aut-affil-num=10 ORCID= en-aut-name=YanaiHiroyuki en-aut-sei=Yanai en-aut-mei=Hiroyuki kn-aut-name=柳井広之 kn-aut-sei=柳井 kn-aut-mei=広之 aut-affil-num=11 ORCID= en-aut-name=OmoriMasako en-aut-sei=Omori en-aut-mei=Masako kn-aut-name=大森昌子 kn-aut-sei=大森 kn-aut-mei=昌子 aut-affil-num=12 ORCID= affil-num=1 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=2 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=3 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=4 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=5 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=6 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=7 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=8 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=9 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=10 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学 affil-num=11 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　病理部 affil-num=12 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　病理部 en-keyword=乳管洗浄細胞診 (Ductal lavage cytology) kn-keyword=乳管洗浄細胞診 (Ductal lavage cytology) en-keyword=乳癌 (breast cancer) kn-keyword=乳癌 (breast cancer) en-keyword=診断 (diagnosis) kn-keyword=診断 (diagnosis) END start-ver=1.4 cd-journal=joma no-vol=118 cd-vols= no-issue=2 article-no= start-page=119 end-page=121 dt-received= dt-revised= dt-accepted= dt-pub-year=2006 dt-pub=20060901 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Discrepancies between pathological examination and imaging analysis after primary systemic chemotherapy for breast cancer: report of two cases kn-title=乳癌術前化学療法の効果判定における画像診断 われわれが経験した病理判定と画像診断の不一致症例について en-subtitle= kn-subtitle= en-abstract= kn-abstract=Primary systemic chemotherapy (PSC) in breast cancer prolongs disease-free survival in patients who have obtained pathological complete remission (pCR). In combination with pathological examination, CT and MRI have been used to evaluate the efficacy of PSC, they generally coincide well with pathological evaluation. We here present two cases showing discrepancies between pathological examination and imaging analysis after PSC in breast cancer. We should keep such discrepancies in mind to determine the ideal treatment after PSC. An accurate method of evaluating cellular damage by PSC is needed. en-copyright= kn-copyright= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=1 ORCID= en-aut-name=TabuchiYoko en-aut-sei=Tabuchi en-aut-mei=Yoko kn-aut-name=田渕陽子 kn-aut-sei=田渕 kn-aut-mei=陽子 aut-affil-num=2 ORCID= en-aut-name=ItoMitsuya en-aut-sei=Ito en-aut-mei=Mitsuya kn-aut-name=伊藤充矢 kn-aut-sei=伊藤 kn-aut-mei=充矢 aut-affil-num=3 ORCID= en-aut-name=OnoRyoko en-aut-sei=Ono en-aut-mei=Ryoko kn-aut-name=小野亮子 kn-aut-sei=小野 kn-aut-mei=亮子 aut-affil-num=4 ORCID= en-aut-name=ImadaTakako en-aut-sei=Imada en-aut-mei=Takako kn-aut-name=今田孝子 kn-aut-sei=今田 kn-aut-mei=孝子 aut-affil-num=5 ORCID= en-aut-name=MotokiTakayuki en-aut-sei=Motoki en-aut-mei=Takayuki kn-aut-name=元木崇之 kn-aut-sei=元木 kn-aut-mei=崇之 aut-affil-num=6 ORCID= en-aut-name=MatsukawaHiroyosi en-aut-sei=Matsukawa en-aut-mei=Hiroyosi kn-aut-name=松川啓義 kn-aut-sei=松川 kn-aut-mei=啓義 aut-affil-num=7 ORCID= en-aut-name=OhmoriMasako en-aut-sei=Ohmori en-aut-mei=Masako kn-aut-name=大森昌子 kn-aut-sei=大森 kn-aut-mei=昌子 aut-affil-num=8 ORCID= en-aut-name=YanaiHiroyuki en-aut-sei=Yanai en-aut-mei=Hiroyuki kn-aut-name=柳井広之 kn-aut-sei=柳井 kn-aut-mei=広之 aut-affil-num=9 ORCID= en-aut-name=NaomotoYoshio en-aut-sei=Naomoto en-aut-mei=Yoshio kn-aut-name=猶本良夫 kn-aut-sei=猶本 kn-aut-mei=良夫 aut-affil-num=10 ORCID= en-aut-name=TanakaNoriaki en-aut-sei=Tanaka en-aut-mei=Noriaki kn-aut-name=田中紀章 kn-aut-sei=田中 kn-aut-mei=紀章 aut-affil-num=11 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=2 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=3 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=4 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=5 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=6 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=7 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=8 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　病理部 affil-num=9 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　病理部 affil-num=10 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 affil-num=11 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　消化器腫瘍外科 en-keyword=術前化学療法（Primary Systemic Chemotherapy） kn-keyword=術前化学療法（Primary Systemic Chemotherapy） en-keyword=画像診断（Imaging Analysis） kn-keyword=画像診断（Imaging Analysis） en-keyword=MRI kn-keyword=MRI en-keyword=CT kn-keyword=CT END